| Metric | This Period | Prior Year | YoY |
|---|---|---|---|
| Revenue / Net Sales | ¥8116.4B | ¥8072.0B | +0.5% |
| Operating Income | ¥328.9B | ¥400.5B | -17.9% |
| Ordinary Income | ¥288.7B | ¥328.6B | -12.1% |
| Net Income | ¥228.4B | ¥177.9B | +28.4% |
| ROE | 4.4% | 3.6% | - |
FY2025 full-year results showed Revenue ¥8,116B (YoY +¥44B +0.5%) with a marginal increase, while Operating Income was ¥328B (YoY -¥72B -17.9%) and Ordinary Income was ¥288B (YoY -¥40B -12.1%), both down. Net Income attributable to owners of the parent was ¥228B (YoY +¥51B +28.4%), an increase. The company turned a decrease in operating profit into final net income growth primarily through recognition of Special Gains ¥255B centered on Investment Securities Disposal Gains ¥227B. Operating margin declined to 4.1% from 4.96% a year earlier (down 0.9pt). Gross margin slightly fell to 27.8% from 27.9%, and an increase in SG&A ratio to 23.7% pressured profitability.
Revenue ¥8,116B (YoY +0.5%) was broadly flat. By segment, Health Care Solutions (Revenue ¥830B, +7.3%) and Nutrition Solutions (Revenue ¥2,061B, +5.7%) were drivers; Quality of Life Solutions (Revenue ¥1,944B, +1.8%) also posted modest growth, while the core Material Solutions (Revenue ¥3,275B, -4.6%) declined and dragged on consolidated results. By region: Japan ¥448B (prior ¥440B) slightly up; Asia ¥163B (prior ¥170B) down; North America ¥75B (prior ¥77B) slightly down; Europe ¥84B (prior ¥83B) flat; Other ¥42B (prior ¥36B) up. Soft Asian markets and lower Material sales were headwinds, partially offset by growth in healthcare and nutrition solutions.
Operating Income ¥328B (YoY -17.9%) declined significantly. Cost of sales was ¥5,861B (+4.8%), far outpacing revenue growth (+0.5%), leaving Gross Profit ¥2,256B (-0.04%) effectively flat. Gross margin was 27.8% (down 0.1pt YoY), indicating delayed pass-through of raw material and energy cost increases. SG&A was ¥1,927B (+3.8%), increasing faster than sales, and SG&A ratio rose to 23.7% (up 0.8pt YoY). Group-wide expenses include baseline R&D and their increase weakened operating leverage. By segment, Material Solutions Operating Income was ¥249B (-19.5%), a large decline; Quality of Life Solutions Operating Income was ¥179B (-10.4%); conversely, Health Care Solutions Operating Income was ¥148B (+10.8%) and Nutrition Solutions Operating Income was ¥137B (+4.9%), with Health Care’s high profitability (margin 17.9%) providing support. Ordinary Income ¥288B (YoY -12.1%) reflected the operating decline but was partially covered by Equity in Earnings of Affiliates ¥1B and Dividend Income ¥19B. Net Special Gains ¥255B (mainly Investment Securities Disposal Gains ¥227B) less Special Losses ¥96B (mainly Impairment Losses ¥24B, Loss on Retirement of Fixed Assets ¥25B) produced a net ¥159B uplift to profit before tax, resulting in Profit Before Tax ¥448B (prior ¥367B, +21.8%). After Income Taxes ¥122B (effective tax rate 27.2%) and Non-controlling Interests ¥16B, Net Income attributable to owners of the parent was ¥228B (+28.4%). Note that one-time gains account for roughly 51% of profit, in contrast to weaker core operations; in sum, the company posted revenue growth with operating decline but converted to final net income growth via special gains.
Material Solutions Unit: Revenue ¥3,275B (-4.6%), Operating Income ¥249B (-19.5%), margin 7.6%. Market softening and lower sales caused revenue decline and cost increases materially reduced margins. Quality of Life Solutions Unit: Revenue ¥1,944B (+1.8%), Operating Income ¥179B (-10.4%), margin 9.2%. Slight revenue growth but compressed profits, indicating weak cost absorption. Health Care Solutions Unit: Revenue ¥830B (+7.3%), Operating Income ¥148B (+10.8%), margin 17.9%. High-margin stable growth, the largest contributor to consolidated profits. Nutrition Solutions Unit: Revenue ¥2,061B (+5.7%), Operating Income ¥137B (+4.9%), margin 6.7%. Achieved revenue and profit growth on solid demand. Others (insurance agency, etc.): Revenue ¥25B (+8.7%), Operating Income ¥5B (+6.6%), margin 21.8%, small scale but high profitability.
Profitability: Operating margin 4.1%, Ordinary profit margin 3.6%, Net margin 2.8%; Operating margin down 0.9pt YoY, Net margin up 0.6pt YoY. Gross margin 27.8%, SG&A ratio 23.7%, EBITDA ¥803B (9.9% of Revenue). Depreciation & amortization including goodwill amortization ¥5B totals ¥474B, indicating high fixed-cost burden. ROE 4.4% declined from 5.5% prior year. Equity Ratio 54.4% slightly up from 53.5%, limiting leverage effect. Decline at the operating level is the primary driver of ROE pressure.
Cash quality: Operating Cash Flow (OCF) ¥501B, Free Cash Flow (FCF) ¥240B; OCF/Net Income 1.62x, indicating good cash conversion. Accrual ratio -2.0% implies small accounting accrual build-up, but OCF/EBITDA is only 0.62x, suggesting working capital drag on cash generation.
Investment efficiency: Capex ¥488B vs Depreciation ¥474B, Capex/D&A 1.03x, indicating slight expansion focused on maintenance/renewal. Construction in progress ¥595B (prior ¥453B, +31%) signals progress on investment projects. FCF ¥240B covers Dividends Paid ¥82B and Share Buybacks ¥120B (Total return ¥202B), indicating sustainable internal funding.
Financial soundness: Equity Ratio 54.4%, Current Ratio 153%, Quick Ratio 117%—short-term liquidity acceptable. Interest-bearing debt ¥1,986B, Debt/EBITDA 2.47x, Interest Coverage 8.04x—within investment-grade range. However, Short-term borrowings ¥1,395B vs Cash & Deposits ¥510B yields Cash/Short-term Debt 0.37x and short-term debt reliance 70%, exposing refinancing sensitivity as a concern.
OCF ¥501B (YoY +21.5%); subtotal before working capital changes ¥648B, with working capital movements (Inventory -¥30B, Trade Receivables -¥10B, Trade Payables -¥88B, Other -¥7B totaling -¥135B) and Income Taxes Paid -¥120B resulting in the final level. Investing CF was -¥261B, driven mainly by Capex -¥488B partially offset by Investment Securities Sale Proceeds ¥255B. FCF ¥240B (prior -¥138B) benefited substantially from investment securities disposals. Financing CF was -¥200B, with Long-term borrowings proceeds ¥66B vs repayments -¥67B, Short-term borrowings increase ¥35B, Dividends paid -¥93B, and Share buybacks -¥120B as primary items. Ending cash ¥489B (prior ¥446B, +9.6%). Working capital pressure from increases in inventory and receivables and decrease in payables constrained OCF. CCC 150 days (DSO 74 days, DIO 127 days, DPO 51 days) shows elongation in inventory and receivables, weakening cash conversion. OCF/Net Income 1.62x is healthy, but OCF/EBITDA 0.62x indicates room for improvement.
Ordinary Income ¥288B comprises Operating Income ¥329B and Non-operating income/expense net -¥40B (Non-operating income ¥50B - Non-operating expenses ¥90B). Core business is the main source. Major non-operating items: Dividend income ¥19B, Foreign exchange gains ¥15B; major non-operating expense: Interest expense ¥41B. Net Special Gains ¥255B (Investment Securities Disposal Gains ¥227B, Negative Goodwill ¥3B, etc.) less Special Losses ¥96B (Impairment Losses ¥24B, Loss on Retirement of Fixed Assets ¥25B, Disaster Losses ¥6B, etc.) produced a net ¥159B uplift to profit before tax and account for about 70% of Net Income ¥228B. Heavy reliance on non-recurring items implies weak ability to generate net income from recurring operations. OCF ¥501B is 1.62x Net Income indicating good cash quality, but Comprehensive Income ¥508B (Other Comprehensive Income ¥182B consisting of Foreign Currency Translation Adjustments ¥130B, Remeasurements of Defined Benefit Plans ¥90B, Valuation Differences on Securities -¥38B) exceeded Net Income, showing valuation movements materially affect equity. Accrual ratio -2.0% indicates limited accounting accrual build-up, but low OCF/EBITDA 0.62x highlights working capital management issues.
Full-year guidance: Revenue ¥8,200B (+1.0%), Operating Income ¥360B (+9.4%), Ordinary Income ¥320B (+10.8%), Net Income attributable to owners of the parent ¥315B (EPS ¥523), Dividend ¥105. Actuals: Revenue ¥8,116B (achievement 99.0%), Operating Income ¥329B (91.4%), Ordinary Income ¥289B (90.2%), Net Income ¥228B (72.4%, company plan ¥315B). Shortfalls are notable at operating and ordinary income levels. Operating income shortfall stems from Material Solutions profitability decline and higher group-wide expenses; shortfall in final net income reflects lower-than-expected special gains relative to company projections. Dividend guidance ¥105 vs actual ¥160 (interim ¥80 + year-end ¥80) outperformed forecast, likely reflecting stronger shareholder returns due to additional special gains.
Annual dividend ¥160 (Interim ¥80, Year-end ¥80), a substantial increase from prior year ¥60. Payout Ratio 32.4% (based on EPS ¥501) within appropriate range. Dividends paid ¥82B vs FCF ¥240B gives FCF coverage 2.9x, indicating high sustainability. Share buybacks ¥120B executed, total return ¥202B, Total Return Ratio approximately 65%. Buybacks were within FCF capacity; combined with dividend payout ratio ~32%, total returns are comfortably covered by FCF. The large beat to company dividend plan (¥160 actual vs ¥105 forecast) signals a shareholder return focus backed by special gains. Sustainability going forward depends on stable OCF (improvement in OCF/EBITDA) and recovery in core operating earnings.
Structural decline risk in Material Solutions profitability: The core Material Solutions segment (Operating Income ¥249B, -19.5%) could continue to suffer from market softening and inability to pass on raw material cost inflation, reducing margins to 7.6%. Continued demand slowdown and cost inflation could materially compress consolidated operating income given this segment’s roughly 75% share of consolidated operating profit. With Debt/EBITDA at 2.47x, further operating income deterioration could worsen financial metrics and affect refinancing terms.
Liquidity risk from working capital build-up: Inventory ¥1,108B (prior ¥1,042B +6.3%), Trade Receivables ¥1,636B (prior ¥1,579B +3.6%) indicate expanding working capital; with DIO 127 days, DSO 74 days, CCC 150 days elongating. Short-term borrowings ¥1,395B vs Cash & Deposits ¥510B produce Cash/Short-term Debt 0.37x and 70% short-term debt reliance. Further working capital deterioration could raise refinancing pressure and borrowing costs. Low OCF/EBITDA 0.62x highlights urgent need to improve working capital management.
Earnings volatility risk from dependence on one-time gains: Of Net Income ¥228B, net Special Gains ¥159B (approx. 70%) contributed materially, indicating a fragile recurring earnings base. Investment Securities Disposal Gains ¥227B are non-recurring; their absence in future periods could lead to sharp declines in Net Income. While Dividend ¥160 (Total return ¥202B) is currently covered by OCF ¥501B, prolonged operating weakness combined with loss of one-time gains may necessitate reevaluation of dividend policy.
Profitability & Returns
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Margin | 4.1% | 7.8% (4.6%–12.3%) | -3.7pt |
| Net Margin | 2.8% | 5.2% (2.3%–8.2%) | -2.4pt |
Profitability is well below industry median, with both operating and net margins in the lower range.
Growth & Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth (YoY) | 0.5% | 3.7% (-0.4%–9.3%) | -3.2pt |
Revenue growth trails the industry median by 3.2pt.
※ Source: Company compilation
Expansion of high-margin healthcare segment and potential for group margin improvement: Continued growth in Health Care Solutions (margin 17.9%, +10.8%) and Nutrition Solutions (margin 6.7%, +4.9%) could lift consolidated margins. Recovery in Material Solutions profitability (margin 7.6%, -19.5%) is a medium-term priority; increasing the share of healthcare, price adjustments, and mix improvement are keys to restoring operating margin into the 5% range.
Potential cash generation from improved working capital efficiency: Shortening CCC 150 days (DIO 127 days, DSO 74 days) offers significant upside to OCF. If inventory and receivables management improves and OCF/EBITDA moves from the 0.6x range to above 0.8x, FCF expansion and reduced short-term debt reliance would enhance financial soundness.
Balance between shareholder returns and core earnings power: Total return ¥202B (Dividends ¥82B + Buybacks ¥120B) is covered by FCF ¥240B and sustainable for now. However, persistence of Dividend ¥160 depends on recovery in operating profit. Payout Ratio 32% is within an appropriate range, but achievement of Operating Income ¥360B (company plan +9.4%) will determine scope for future dividend increases.
This report is an AI-generated financial analysis document produced by analyzing XBRL earnings announcement data. It is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled by the company from public financial statements. Investment decisions are your responsibility; consult a professional advisor as needed.